O2-8-1Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial

Ohkawa, Shinichi; Okusaka, Takuji; Kudo, Masatoshi; Hatano, Etsuro; Fujii, Hirofumi; Masumoto, Akihide; Furuse, Junji; Wada, Yoshiyuki; Ishii, Hiroshi; Obi, Shuntaro; Arai, Kuniaki; Kawazoe, Seiji; Yokosuka, Osamu; Ikeda, Masafumi; Ukai, Katsuaki; Morita, Sojiro; Asou, Hiroya; Abada, Paolo B.; Yang, Ling; Zhu, Andrew X.

期刊名称Annals of Oncology
作者Ohkawa, Shinichi; Okusaka, Takuji; Kudo, Masatoshi; Hatano, Etsuro; Fujii, Hirofumi; Masumoto, Akihide; Furuse, Junji; Wada, Yoshiyuki; Ishii, Hiroshi; Obi, Shuntaro; Arai, Kuniaki; Kawazoe, Seiji; Yokosuka, Osamu; Ikeda, Masafumi; Ukai, Katsuaki; Morita, Sojiro; Asou, Hiroya; Abada, Paolo B.; Yang, Ling; Zhu, Andrew X.
卷第26卷
印刷ISSN0923-7534
电子ISSN1569-8041
文件大小35.45KB
发表时间2015-11
DOI10.1093/annonc/mdv471.63

发现好书期刊，享受阅读乐趣

O2-8-1Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial